Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 16;77(10):1357-1367.
doi: 10.1016/j.jacc.2021.01.011.

A Test in Context: Interpretation of High-Sensitivity Cardiac Troponin Assays in Different Clinical Settings

Affiliations
Free article
Review

A Test in Context: Interpretation of High-Sensitivity Cardiac Troponin Assays in Different Clinical Settings

Inbar Raber et al. J Am Coll Cardiol. .
Free article

Abstract

High-sensitivity cardiac troponin (hs-cTn) assays have the ability to detect minute troponin concentrations and resolve minor changes in biomarker concentrations. Clinically, this allows for the ability to rapidly identify or exclude acute myocardial injury in the setting of acute chest discomfort-thus providing more rapid evaluation for acute myocardial infarction-but the improvements in troponin assays also create avenues for other applications where troponin release from the cardiomyocyte might confer prognostic information. These situations include cardiovascular risk assessment across a wide range of clinical circumstances, including apparently-well individuals, those at risk for heart disease, and those with prevalent cardiovascular disorders. The optimal hs-cTn threshold for each circumstance varies by the assay used and by the population assessed. This review will provide context for how hs-cTn assays might be interpreted depending on the application sought, reviewing results from studies leveraging hs-cTn for applications beyond "acute myocardial infarction diagnostic evaluation."

Keywords: biomarkers; high-sensitivity cardiac troponin; risk stratification.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr. Januzzi is supported in part by the Hutter Family Professorship; has served as a trustee of the American College of Cardiology and a board member of Imbria Pharmaceuticals; has received grant support from Novartis Pharmaceuticals and Abbott Diagnostics; has received consulting income from Abbott, Janssen, Novartis, and Roche Diagnostics; and has participated in clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Amgen, Janssen, and Takeda. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Publication types

LinkOut - more resources